Regeneron speeds toward the FDA with its would-be asthma blockbuster – FierceBiotech

Regeneron speeds toward the FDA with its would-be asthma blockbuster
FierceBiotech
Meanwhile, after meeting with the FDA, Regeneron now believes the agency will recognize an earlier Phase IIb asthma study as one of two required pivotal trials. In that trial, the highest doses of dupilumab significantly beat out placebo in improving
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Benzinga

all 4 news articles »

View full post on asthma – Google News